[1] |
Hao Mingxiao, Mi Jie, Xu Zongyi.
Effectiveness of a continuity of care model in patients with tuberculous meningitis
[J]. Chinese Journal of Antituberculosis, 2025, 47(4): 477-481.
|
[2] |
Huang Misun, Wu Yaning, Li Guilian, Liu Haican.
Research advances of Mycobacterium tuberculosis enrichment technology
[J]. Chinese Journal of Antituberculosis, 2025, 47(3): 369-373.
|
[3] |
Zhao Yue, Wang Haoran, Cheng Meijin, Wang Wei, Liang Ruixia, Huang Hairong.
The evaluation of the smear-positive and Xpert-negative outcome as an early indicator of nontuberculous mycobacteria existence in clinical specimen
[J]. Chinese Journal of Antituberculosis, 2025, 47(1): 61-65.
|
[4] |
Lu Hailin, Wang Wenfei, Tao Wenhui, Lin Peicong, Chen Xinchun, Deng Guofang, Xie Shuixiang.
Oleic acid upregulates the expression of perilipin 2 enhancing macrophage clearance of Mycobacterium tuberculosis
[J]. Chinese Journal of Antituberculosis, 2025, 47(1): 72-76.
|
[5] |
Geng Zimei, Wang Chaohong, Long Sibo, Zheng Maike, Shi Yiheng, Sun Yong, Zhao Yan, Wang Guirong.
Analysis of bacteriological positivity and rifampicin resistance in patients with severe pulmonary tuberculosis
[J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1050-1055.
|
[6] |
Wang Fei, Hua Duo, Guo Jianjian, Liu Chang, Han Lu, Ren Yi.
Characteristic analysis of non-tuberculous mycobacterial pulmonary disease patients in Wuhan area from 2021 to 2023
[J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1069-1076.
|
[7] |
Palidanguli Abudureheman, Wang Senlu, Gulina Badeerhan, Wang Le, Zulikatiayi Abudula, Wang Xinqi, Maiwulajiang Yimamu, Wang Xijiang.
Distribution of Mycobacterium tuberculosis genotypes in Kashgar region and their association with clinical characteristics of pulmonary tuberculosis patients
[J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1077-1082.
|
[8] |
Yang Liangzi, Zhang Peize, Lu Shuihua.
Interpretation of World Health Organization’s Co-administration of Treatment for Drug-resistant Tuberculosis and Hepatitis C: 2024 Update
[J]. Chinese Journal of Antituberculosis, 2024, 46(8): 874-876.
|
[9] |
Yu Lan, Chen Shuangshuang, Wang Nenhan, Tian Lili, Zhao Yanfeng, Fan Ruifang, Liu Haican, Li Chuanyou, Dai Xiaowei.
Consistency between phenotypic resistance to fluoroquinolones and genetic mutations in rifampicin resistant Mycobacterium tuberculosis strains
[J]. Chinese Journal of Antituberculosis, 2024, 46(8): 942-950.
|
[10] |
Ye Xinchun, Liu Saiduo, Cheng Fang, Jiang Xiangao, Ning Hongye, Wu Zhengxing, Zhou Yueying, Qiu Chaochao, Pan Ning, Shi Jichan.
Risk factors of latent tuberculosis infection among close contacts of drug-resistant pulmonary tuberculosis patients
[J]. Chinese Journal of Antituberculosis, 2024, 46(5): 525-530.
|
[11] |
Bao Xundi, Liang Suo, Li Jun, Ye Qian, Wu Dandan, Wang Shu, LI Yue, Ding Yunsheng, Liu Jie.
Analysis of Mycobacterium tuberculosis drug resistance monitoring in Anhui Province from 2016 to 2022
[J]. Chinese Journal of Antituberculosis, 2024, 46(5): 531-537.
|
[12] |
Yang Jing, Xiao Lijuan, Fang Tanwei.
Development strategy and prospect of tuberculosis mRNA vaccines
[J]. Chinese Journal of Antituberculosis, 2024, 46(5): 590-595.
|
[13] |
Cheng Mengli, Jiang Guanglu, Huo Fengmin, Xue Yi, Yu Xia.
Evaluation of in vitro activity of fusidic acid against mycobacteria
[J]. Chinese Journal of Antituberculosis, 2024, 46(4): 461-466.
|
[14] |
Pei Shaojun, Ou Xichao.
Interpretation of the World Health Organization’s Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance (2nd Edition)
[J]. Chinese Journal of Antituberculosis, 2024, 46(3): 260-266.
|
[15] |
Ma Shiran, Chen Suting, Huang Hairong, Duan Hongfei.
In vitro inhibitory and intracellular bactericidal activity of omadacycline against Mycobacterium abscessus
[J]. Chinese Journal of Antituberculosis, 2024, 46(12): 1442-1447.
|